NEW YORK, NY / ACCESSWIRE / February 16, 2018 / U.S. markets continued to rally for the fifth consecutive day on Thursday, after being hit with a sharp correction last week. The Dow Jones Industrial Average gained 1.23 percent to close at 25,200.37, while the S&P 500 jumped 1.21 percent to close at 2,731.20. The Nasdaq Composite Index spiked 1.58 percent to close at 7,256.43, as tech giants Alphabet and Netflix all posted gains. Last week on February 8th the major indexes closed down 10 percent from the highs set on January 26th.

"The volatility we saw in that correction is here to stay," said Maris Ogg, president at Tower Bridge Advisors, according to CNBC. "We don't have the dampening mechanisms we had in previous years. ... But frankly, the path of least resistance is still up and fundamentals haven't really changed.".

RDI Initiates Coverage on:

Sarepta Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=SRPT

Valeant Pharmaceuticals Intl Inc.
https://rdinvesting.com/news/?ticker=VRX

Sarepta Therapeutics? stock jumped 5.99% Thursday, to close the day at $63.14. The stock recorded a trading volume of 1,802,423 shares, which was above its three months average volume of 1,597,241 shares. In the last year, Sarepta Therapeutics? shares have traded in a range of 26.96 - 68.90. The share price has gained 134.20% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $60.80 is greater than its 200-day moving average of $51.04. Shares of Sarepta Therapeutics have gained roughly 2.63 percent in the past month and are up 13.48 percent year-to-date.

Access RDI's Sarepta Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SRPT

On Thursday, shares of Valeant Pharmaceuticals recorded a trading volume of 8,392,371 shares, which was below the three months average volume of 16,773,617 shares. The stock ended the day 1.63% higher at 18.67. The share price has gained 124.67% from its 52-week low with a 52-week trading range of 8.31 - 24.43. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $20.64 is greater than its 200-day moving average of $16.41. Shares of Valeant Pharmaceuticals are trading at a Price to Earnings ratio of 4.76. Shares of Valeant Pharmaceuticals have fallen roughly 21.69 percent in the past month and are down 10.15 percent year-to-date.

Access RDI's Valeant Pharmaceuticals Intl Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VRX

Our Actionable Research on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com